Aditxt Announces Proposed Public Offering of Common Stock and Warrants
November 30 2021 - 7:14PM
Business Wire
Aditxt, Inc. (“Aditxt”) (Nasdaq: ADTX), a biotech innovation
company with a mission to improve the health of the immune system,
announced today the launch of an underwritten public offering.
Dawson James Securities, Inc. is acting as sole book-running
manager for the offering.
The proposed offering of the common stock and warrants described
above is being made pursuant to an effective “shelf” registration
statement on Form S-3 (File No. 333-257645), that was previously
filed with the Securities and Exchange Commission ("SEC") and
declared effective by the SEC on July 13, 2021, and the base
prospectus contained therein. Such shares of common stock and
warrants may be offered only by means of a prospectus, including a
prospectus supplement.
A prospectus supplement and accompanying prospectus related to
the offering of common stock will be filed with the SEC and will be
available on the SEC's website located at http://www.sec.gov.
Copies of the prospectus supplement and the accompanying prospectus
relating to the offering of common stock and warrants may be
obtained, when available, by contacting Dawson James Securities,
Inc., Attention: Prospectus Department, 101 North Federal Highway,
Suite 600, Boca Raton, FL, 33432, cwachowiz@dawsonjames.com or toll
free at 866.928.0928.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy any securities nor will there be
any sale of these securities in any state or other jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or other jurisdiction.
About Aditxt
Aditxt is developing technologies specifically focused on
improving the health of the immune system through immune monitoring
and reprogramming. Aditxt's immune monitoring technology is
designed to provide a personalized comprehensive profile of the
immune system. Aditxt's immune reprogramming technology is
currently at the pre-clinical stage and is designed to retrain the
immune system to induce tolerance with an objective of addressing
rejection of transplanted organs, autoimmune diseases, and
allergies. For more information, please visit: www.aditxt.com.
Forward-Looking Statements
Certain statements in this
press release constitute "forward-looking statements" within the
meaning of federal securities laws. Forward-looking statements in
this press release include, without limitation, the ability of the
Company to close the offering. Forward-looking statements include
statements regarding the Company's intentions, beliefs,
projections, outlook, analyses or current expectations concerning,
among other things, the Company's ongoing and planned product and
business development; the Company's intellectual property position;
the Company's ability to develop commercial functions; expectations
regarding product launch and revenue; the Company's results of
operations, cash needs, spending, financial condition, liquidity,
prospects, growth and strategies; the industry in which the Company
operates; and the trends that may affect the industry or the
Company. Forward-looking statements are not guarantees of future
performance and actual results may differ materially from those
indicated by these forward-looking statements as a result of
various important factors, as well as those risks more fully
discussed in the section titled "Risk Factors" in the Company's
most recent Annual Report on Form 10-K, as well as discussions of
potential risks, uncertainties, and other important factors in the
Company's other filings with the Securities and Exchange
Commission. All such statements speak only as of the date made, and
the Company undertakes no obligation to update or revise publicly
any forward-looking statements, whether as a result of new
information, future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211130006156/en/
Aditxt, Inc. ir@aditxt.com
Aditxt (NASDAQ:ADTX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aditxt (NASDAQ:ADTX)
Historical Stock Chart
From Jul 2023 to Jul 2024